- Home
- GRX vs CKPT Comparison
GRX vs CKPT Comparison
Compare GRX & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRX
- CKPT
- Stock Information
- Founded
- GRX 2007
- CKPT 2014
- Country
- GRX United States
- CKPT United States
- Employees
- GRX N/A
- CKPT N/A
- Industry
- GRX Finance/Investors Services
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- GRX Finance
- CKPT Health Care
- Exchange
- GRX Nasdaq
- CKPT Nasdaq
- Market Cap
- GRX 164.6M
- CKPT 142.3M
- IPO Year
- GRX N/A
- CKPT 2017
- Fundamental
- Price
- GRX $10.37
- CKPT $3.37
- Analyst Decision
- GRX
- CKPT Strong Buy
- Analyst Count
- GRX 0
- CKPT 3
- Target Price
- GRX N/A
- CKPT $12.00
- AVG Volume (30 Days)
- GRX 39.7K
- CKPT 892.6K
- Earning Date
- GRX 01-01-0001
- CKPT 03-21-2025
- Dividend Yield
- GRX 5.98%
- CKPT N/A
- EPS Growth
- GRX N/A
- CKPT N/A
- EPS
- GRX 0.26
- CKPT N/A
- Revenue
- GRX N/A
- CKPT $47,000.00
- Revenue This Year
- GRX N/A
- CKPT N/A
- Revenue Next Year
- GRX N/A
- CKPT $172,016.02
- P/E Ratio
- GRX $38.50
- CKPT N/A
- Revenue Growth
- GRX N/A
- CKPT N/A
- 52 Week Low
- GRX $7.73
- CKPT $1.38
- 52 Week High
- GRX $10.40
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- GRX 66.23
- CKPT 50.00
- Support Level
- GRX $9.62
- CKPT $2.77
- Resistance Level
- GRX $10.48
- CKPT $2.90
- Average True Range (ATR)
- GRX 0.14
- CKPT 0.19
- MACD
- GRX 0.07
- CKPT 0.01
- Stochastic Oscillator
- GRX 83.33
- CKPT 66.22
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.